Genomic Health says new study confirms Oncotype DX helps predict likelihood of breast cancer survival

New York, May 31 - Genomic Health, Inc. reported that a new clinical study confirms that its breast cancer test service Oncotype DX also helps predict the likelihood of breast cancer survival.

The research, carried out by Kaiser Permanente, looked at women with lymph node-negative breast cancer.

It found a statistically significant correlation between the Oncotype DX Recurrence Score and breast cancer survival. Specifically, risk of death from breast cancer at 10 years was 2.8% for women with a Recurrence Score less than 18, 10.7% for women with a Recurrence Score between 18 and 31, and 15.5% for women with a Recurrence Score greater than or equal to 31.

"This landmark, first-of-its-kind epidemiological study in breast cancer demonstrates a statistically significant association between the Oncotype DX Recurrence Score and survival, independent of traditional measures such as tumor size and grade," Laurel Habel, an investigator with Kaiser Permanente's division of research and the lead author of the study, said in a news release.

The researchers compared archived tissue from 220 patients who died with 570 matched control patients.

Genomic Health is a Redwood City, Calif., life sciences company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.